Ipilimumab (Yervoy) for ‘treatment of advanced (unresectable or metastatic) melanoma in adults

In a single phase-3 study in patients with advanced (stage III or IV) melanoma who had been treated previously, and had a positive status for HLA-A2*0201, ipilimumab significantly improved the median overall survival in comparison with the GP100 vaccine.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.